The global dermatophytosis treatment market is estimated to garner a large amount of revenue by growing at a robust CAGR over the forecast period, i.e., 2022 – 2030. The growth of the market can be attributed to the growing population of people with weak immune systems, and rising incidences of sedentary lifestyle among people. Along with these, increasing geriatric population contributing to the high occurrence of dermatophytosis across the globe is also expected to significantly raise the demand for the treatment in the forthcoming years. According to the World Health Organization, between 2015 to 2050, the percentage of the world’s population aged 60 years and older will nearly double from 12 percent to 22 percent. In 2050, 80% of older people will be living in low- and middle-income countries.
Upsurge in the number of hospital-acquired diseases is also predicted to expand the market in the near future. Furthermore, escalating private investments for conducting research and development activities to develop novel treatment in developed nations, and rise in healthcare funding are assessed to offer profitable opportunities for market growth in the imminent time.
Get more information on this report: Download Sample PDF
The market is segmented by drug used into imidazole, econazole, clotrimazole, miconazole, ketoconazole, terbinafine, clotrimazole, corticosteroid, terbinafine, itraconazole, griseofulvin, and others, out of which, the itraconazole segment is anticipated to hold the largest share in the global dermatophytosis treatment market. This can be accounted to the broad antifungal spectrum and excellent effectiveness of this drug against fungal infections. Apart from these, high usage of itraconazole capsules for treating infections of the toenails is also projected to drive the segment’s growth in the future. Additionally, on the basis of end user, the clinics segment is evaluated to grab the largest share during the forecast period owing to the growing preference of patients to get treated by medical professionals operating in a specialty clinic facility.
According to the statistics by the World Health Organization, the global per capita healthcare expenditure amounted to USD 1,064.741 in the year 2017. The worldwide healthcare expenditure per person grew from USD 864.313 in 2008 to USD 1,110.841 in 2018, where the U.S. is the top country that amounted to healthcare expenditure of USD 10, 623.85 per capita in 2018. As of 2018, the domestic general government healthcare spending in the U.S. was USD 5355.79, which grew from USD 3515.82 in 2008. These are some of the factors responsible for market growth over the past few years. Moreover, as per the projections by the Centers for Medicare & Medicaid Services (CMS), the estimated average annual percent change related to National Health Expenditures (NHE) in the U.S. was 5.2% in 2020 as compared to 2019 (4.5%). Furthermore, the National Health Expenditures are projected to reach USD 6,192.5 Billion in 2028, where the per capita expenditure is estimated to touch USD 17,611 in the same year. These are notable indicators that are anticipated to create lucrative business opportunities in upcoming years.
On the basis of geographical analysis, the global dermatophytosis treatment market is segmented into five major regions including North America, Europe, Asia Pacific, Latin America and the Middle East & Africa region. The market in the Asia Pacific is estimated to witness noteworthy growth over the forecast period on the back of the increasing geriatric population, and significant improvements in the healthcare facility in the region. In addition, rise in disposable income and literacy levels is also projected to boost the region’s market growth in the coming years. In the ASEAN region, Singapore accounts for the highest disposable income of approximately USD 30 thousand as of 2021, whereas Malaysia’s disposable income is calculated to reach a value of close to USD 5 thousand. Moreover, the market in North America is anticipated to acquire the largest share during the forecast period ascribing to the availability of highly developed healthcare infrastructure, favorable reimbursement policies, and growing awareness about the benefits of early diagnosis of the disease.
Get more information on this report: Download Sample PDF
The global dermatophytosis treatment market is further classified on the basis of region as follows:
Our in-depth analysis of the global dermatophytosis treatment market includes the following segments:
FREQUENTLY ASKED QUESTIONS
The major factors driving market growth are growing population of people with weak immune systems and rising incidences of sedentary lifestyle among people.
The market is anticipated to attain a robust CAGR over the forecast period, i.e., 2022 – 2030.
Availability of alternative treatment options is estimated to hamper the market growth.
Asia Pacific will provide more business opportunities for market growth owing to the increasing geriatric population, and significant improvements in the healthcare facility in the region.
The major players in the market are Galderma S.A., Novartis AG, Pfizer, Inc., Moberg Pharma AB, Janssen Global Services, LLC, and others.
The company profiles are selected based on the revenues generated from the product segment, geographical presence of the company which determine the revenue generating capacity as well as the new products being launched into the market by the company.
The market is segmented by type, drug used, end user, and by region.
The clinics segment is anticipated to hold largest market size and is estimated to grow at a notable CAGR over the forecast period and display significant growth opportunities.
Direct access to analyst to help you understand the market in a better way to handle your critical question
Citing your business specific requirement our consultant would assist you ensuring targeted goal is achieved
Get 10% free customization